Ampicillin News and Research RSS Feed - Ampicillin News and Research

Study reveals humans are passing antibiotic resistance to wildlife in protected areas

Study reveals humans are passing antibiotic resistance to wildlife in protected areas

A team of Virginia Tech researchers has discovered that humans are passing antibiotic resistance to wildlife, especially in protected areas where numbers of humans are limited. [More]
Specific therapy may cut pneumonia mortality in HIV babies

Specific therapy may cut pneumonia mortality in HIV babies

The high mortality rate associated with acute severe pneumonia-related respiratory failure in infants exposed to or infected with HIV can be reduced to 30% if a treatment plan involving antibiotics, ventilation, and fluid restriction is used, researchers report. [More]

Gal-pagos reptiles living near human settlements harbor antibiotic-resistant bacteria

Land and marine iguanas and giant tortoises living close to human settlements or tourist sites in the Gal-pagos islands are more likely to harbor antibiotic-resistant bacteria than those living in more remote or protected sites on the islands, researchers report in a new study. [More]
Roads may play a major role in the spread or containment of antibiotic resistant bacteria

Roads may play a major role in the spread or containment of antibiotic resistant bacteria

Antibiotic resistant E. coli was much more prevalent in villages situated along roads than in rural villages located away from roads, which suggests that roads play a major role in the spread or containment of antibiotic resistant bacteria, commonly called superbugs, a new study finds. [More]
Simple ultrasound examination may avoid complex tests for children with urinary tract infection

Simple ultrasound examination may avoid complex tests for children with urinary tract infection

For infants and young children with urinary tract infection seen in the ER, a simple ultrasound examination may avoid the need for more complex x-ray tests, reports a study in the May issue of The Pediatric Infectious Disease Journal. [More]
Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole. [More]
Otoscopic exams critical for accurate diagnosis of ear infections in children

Otoscopic exams critical for accurate diagnosis of ear infections in children

Among the findings of an analysis of previous studies regarding ear infections in children are that results from otoscopic exams (an instrument for examining the interior of the ear) are critical to accurate diagnosis and antibiotics are modestly more effective than no treatment, with most antibiotics demonstrating similar rates of clinical success among children at normal risk, according to an article in the November 17 issue of JAMA. [More]
Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, completes recruitment of the first group of patients in its US cervical dysplasia (CIN) phase II study of ADXS11-001 as required for the planned DMSB (safety board) meeting scheduled to be held January 11, 2011. [More]
Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has completed the nine (9) doses to be administered to the three (3) vanguard patients in the low dose group of its phase II cervical dysplasia clinical trial study. [More]
Smoking cessation effectively alter subgingival microbiome in patients on periodontal therapy: Study

Smoking cessation effectively alter subgingival microbiome in patients on periodontal therapy: Study

Patients with chronic gum disease who quit smoking in addition to undergoing nonsurgical therapy not only demonstrated a lower abundance of harmful oral pathogens, but also an increase in health-associated bacteria. The researchers from The Ohio State University, Columbus Ohio, and Newcastle University, United Kingdom report their findings in the July 2010 issue of the Journal of Clinical Microbiology. [More]
Ampicillin activates torsinA, improves cell function to reduce movement disorders

Ampicillin activates torsinA, improves cell function to reduce movement disorders

Discovery of an antibiotic's capacity to improve cell function in laboratory tests is providing movement disorder researchers with leads to more desirable molecules with potentially similar traits, according to University of Alabama scientists co-authoring a paper publishing March 10 in the journal Disease Models & Mechanisms. [More]
KAPIDEX to be marketed as DEXILANT in the U.S.

KAPIDEX to be marketed as DEXILANT in the U.S.

Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX™ (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT™ (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. [More]
Antibiotics program of Giant Eagle results in more than $3M in free prescriptions for customers

Antibiotics program of Giant Eagle results in more than $3M in free prescriptions for customers

Pittsburgh-based food and fuel retailer Giant Eagle, Inc. launched its free antibiotics program in September of 2009, and is pleased to announce that the program has resulted in more than $3 million in free prescriptions for customers in the company's four-state operating area. [More]

Low doses of antibiotics may serve as active mutagens and lead to multidrug resistance

Multidrug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) pose a major problem for patients, doctors, and the pharmaceutical industry. To combat such bacteria, it is critical to understand how resistance is developed in the first place. It is commonly thought that an incomplete course of antibiotics would lead to resistance to that particular antibiotic by allowing the bacteria to make adaptive changes under less stringent conditions. [More]
Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs. [More]

New data on KAPIDEX for nighttime heartburn in adults with non-erosive GERD presented at the 2009 ACG

New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001). [More]

Giant Eagle offers generic prescription antibiotics for free at its in-store pharmacies

At a time when many families affected by a difficult economy are struggling with the costs of prescription medications, supermarket retailer Giant Eagle, Inc. is making ten broadly used generic prescription antibiotics in 46 common dosages available for free every day at all of its 210 in-store pharmacies. [More]

Antimicrobial-resistant typhoid fever in U.S. patients is associated with international travel

Infection with an antimicrobial-resistant strain of typhoid fever among patients in the United States is associated with international travel, especially to the Indian subcontinent (India, Pakistan, and Bangladesh), according to a study in the August 26 issue of JAMA. The study also shows an increase in certain strains of typhoid fever that are resistant to the most commonly used medications for treatment. [More]

FDA approves new indication for Wyeth's Tygacil (tigecycline)

Wyeth Pharmaceuticals, a division of Wyeth has announced that the U.S. Food and Drug Administration (FDA) approved Tygacil (tigecycline), for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens. [More]

Discovery of better treatment for bacterial pneumonia

Scientists at St. Jude Children's Research Hospital have demonstrated a more effective treatment for bacterial pneumonia following influenza. [More]